Table of contents
Expand All Topics
COVID-19-associated pulmonary mucormycosis
Guidelines
Key sources
The following summarized guidelines for the evaluation and management of COVID-19-associated pulmonary mucormycosis are prepared by our editorial team based on guidelines from the Academy of Pulmonary Sciences (APS/FISF 2022).
1
Diagnostic investigations
Diagnostic imaging: as per APS/FISF 2022 guidelines, obtain CT with IV contrast in the initial evaluation of patients with COVID-19-associated pulmonary mucormycosis.
E
Show 2 more
More topics in this section
Laboratory tests
Diagnostic procedures
Bronchoscopy: as per APS/FISF 2022 guidelines, perform early flexible bronchoscopy in most patients with COVID-19-associated pulmonary mucormycosis due to the following advantages:
visualization of airway abnormalities
performing endobronchial biopsies
provision of samples representing the lower respiratory tract (bronchoalveolar lavage or bronchial washings).
E
More topics in this section
Biopsy
Medical management
Antifungal therapy, initial: as per APS/FISF 2022 guidelines, administer liposomal amphotericin B 5 mg/kg/day as first-line therapy in patients with COVID-19-associated pulmonary mucormycosis. Consider escalating the dose to 10 mg/kg/day in patients with intracranial involvement.
E
Show 2 more
More topics in this section
Antifungal therapy (maintenance)
Antifungal therapy (treatment failure)